PubMedCrossRef 76. Seve P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, et al.: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. CX-6258 mouse Clin Cancer Res 2007, 13:994–999.PubMedCrossRef 77. Graziano SL, Paris E, Ma X, Selleckchem EPZ015938 Pignon J, Hainaut P, Taron M, Tsao
MS, Kratzke R, Brambilla E, Soria JC: LACE-BIO pooled analysis of the prognostic and predictive value of p53 mutations and expression by immunoistochemistry (IHC) in patients with resected non-small cell lung cancer (NSCLC)- Abs 389P. ESMO Meeting Abstracts 2010., 21: 78. Tsao MS, Hainaut P, Bourredjem A, Janne PA, Pignon J, Douillard Nutlin-3a datasheet J, Soria JC, Seymour L, Shepherd F: LACE-BIO pooled analysis of the prognostic and predictive value of KRAS mutation in completely
resected non small cell lung cancer (NSCLC). Abs 156O. ESMO Meeting Abstracts 2010., 21: 79. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800–808.PubMedCrossRef 80. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, et al.: BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2:e1129.PubMedCrossRef Ergoloid 81. Bria E, Mottolese M, Sperduti I, Visca P, Antoniani B, Facciolo F, Di Modugno F, Cognetti F, Nistico P, Milella M: Prognostic impact of the cytoskeleton regulatory
protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model. ASCO Meeting Abstracts 28:7027. 82. D’Angelo SP, Janjigian YY, Kris MG, Pao W, Riely GJ, Marks J, Sima C, Dycoco J, Park BJ, Azzoli CG: Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. ASCO Meeting Abstracts 28:7011. 83. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527–1537.PubMedCrossRef 84. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450–2456.PubMedCrossRef 85.